B+
Bull case
25%
Probability
Target price
$6.50
+60.5% vs current
MGNX
MacroGenicsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$4.20
+3.7% vs current
B-
Bear case
30%
Probability
Target price
$2.40
-40.7% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+53.4
Score
AI commentary
This is a cautious post-earnings improvement, not a clean bullish turn. The primary company update on May 13, 2026 materially improved the funding narrative by tying Sagard proceeds, expected Bora proceeds and cost actions to runway through 2028, and the stock's immediate reaction was favorable: MGNX closed at $3.45 on May 13, 2026, then $4.16 on May 14, 2026, versus $3.52 on May 12, 2026, before reaching the packet anchor of $4.25 on May 15, 2026. Even so, checked evidence did not show robust delayed analyst revision support by T+3, social context is unavailable, and the peer set is loose rather than direct; the name remains a tentative monitoring story whose next durable move likely requires clinical validation rather than earnings optics alone.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-06-30eventInitial MGC026 clinical data is the nearest pipeline sentiment testHigh impact
MacroGenics said MGC026 dose escalation finished in late 2025, the study is now in dose expansion, and initial clinical data is anticipated in mid-2026. Because the stock remains a low-coverage small-cap biotech despite the improved cash narrative, this readout is still the clearest near-term operating catalyst for a durable rerating [#8-K-2026-05-13].
2026-09-30eventBora manufacturing divestiture closing is now the key balance-sheet rerating checkpointHigh impact
On May 13, 2026, MacroGenics said the planned sale of its manufacturing operations to Bora is expected to bring $122.5 million upfront, and the March 31, 2026 cash balance was $154.2 million before that cash and before transaction fees. Management also said the March 31, 2026 cash balance plus the May Sagard payment, expected Bora proceeds and cost actions support runway through 2028, so a third-quarter 2026 closing would materially reduce near-term financing pressure while a delay would weaken the reset case [#8-K-2026-05-13] [#10-Q-2026-05-13].
2026-12-31catalystMGC028 and broader ADC pipeline milestones remain the bigger second-half proof testHigh impact
MacroGenics said MGC028 continues in Phase 1 dose escalation with initial data expected in the second half of 2026, while MGC030 has an IND planned for the third quarter of 2026. Positive early activity and clean safety would help validate the post-restructuring focus on internal oncology assets, but weak data would likely refocus investors on cash burn and strategic optionality rather than pipeline upside [#8-K-2026-05-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology